HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sustained dapsone-induced remission of hypocomplementemic urticarial vasculitis--a case report.

Abstract
Hypocomplementemic urticarial vasculitis (HUV) is often misdiagnosed. The response to drug therapy may be unsatisfactory, and immunosuppressive therapy may be associated with significant side effects. A 35-year-old patient whose condition was resistant to cyclophosphamide, corticosteroids, pentoxyphylline, cyproheptadine, sulindac, and colchicine was maintained in remission with dapsone, which may be the drug of choice for HUV. Emphysema has been reported to complicate HUV, but this is the first account of vasculitis-related emphysema with no confounding history of tobacco smoke exposure. The relationship of proteolytic injury to the pulmonary and other manifestations is considered, as is the possible role for dapsone in reducing it.
AuthorsA R Eiser, P Singh, H M Shanies
JournalAngiology (Angiology) Vol. 48 Issue 11 Pg. 1019-22 (Nov 1997) ISSN: 0003-3197 [Print] United States
PMID9373057 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Dapsone
Topics
  • Adult
  • Dapsone (therapeutic use)
  • Female
  • Humans
  • Skin (blood supply, drug effects)
  • Urticaria (complications)
  • Vasculitis, Leukocytoclastic, Cutaneous (drug therapy, etiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: